SWOG S1803 (Multiple Myeloma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiply myeloma patients live longer.
Multiple myeloma patients who have received a stem cell transplant
Who Can Participate in the Study?
Adults with multiple myeloma who have had a stem cell transplant.
What is Involved?
If you choose to join this study, you will:
- Be randomly assigned (like flipping a coin) to 1 of 2 groups
-- One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
-- The other group will take lenalidomide alone